Kymera Therapeutics (KYMR) Gains from Sales and Divestitures (2020 - 2026)
Kymera Therapeutics (KYMR) reported Gains from Sales and Divestitures of $189052.0 for Q1 2026, up 28.72% year-over-year from $146869.0 in Q1 2025, and down 33.44% quarter-over-quarter from $284026.0 in Q4 2025.
Kymera Therapeutics (KYMR) Gains from Sales and Divestitures (2020 - 2026) Analysis & Trends
Kymera Therapeutics (KYMR) has 7 years of Gains from Sales and Divestitures data on file, last reported at $189052.0 in Q1 2026.
- Gains from Sales and Divestitures for Q1 2026 came in at $189052.0, up 28.72% year-over-year; the trailing twelve-month figure through Mar 2026 was $189052.0 (up 28.72% YoY), and the FY2025 annual result was $284026.0, up 62.8% from the prior year.
- Gains from Sales and Divestitures slipped to $189052.0 in Q1 2026 per KYMR's latest filing, from $284026.0 in the prior quarter.
- Over five years, Gains from Sales and Divestitures peaked at $284026.0 in Q4 2025 and troughed at $14215.0 in Q1 2022.
- A 5-year average of $115720.4 and a median of $83209.0 in 2024 frame the typical range for Gains from Sales and Divestitures.
- The sharpest annual moves came in 2022 and 2024: Gains from Sales and Divestitures slumped 56.56% in 2022, then jumped 371.47% in 2024.
- A 5-year view of Gains from Sales and Divestitures shows it stood at $36866.0 in 2022, then advanced by 7.17% to $39511.0 in 2023, then jumped by 341.56% to $174463.0 in 2024, then surged by 62.8% to $284026.0 in 2025, then plunged by 33.44% to $189052.0 in 2026.
- Business Quant data shows KYMR's Gains from Sales and Divestitures at $189052.0 in Q1 2026, $284026.0 in Q4 2025, and $278130.0 in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Alterity Therapeutics | 925,601.88 Bn | 925,601.85 Bn | - |
| 2 | Belite Bio | 58,560.00 Bn | 58,560.00 Bn | - |
| 3 | Quantum Biopharma | 17,284.41 Bn | 17,284.40 Bn | - |
| 4 | Legend Biotech | 2,809.00 Bn | 2,808.71 Bn | 242.10 Mn |
| 5 | Evaxion A | 1,334.43 Bn | 1,334.42 Bn | - |
| 6 | Akari Therapeutics | 1,312.27 Bn | 1,312.26 Bn | - |
| 7 | Psyence Biomedical | 212.16 Bn | 212.16 Bn | - |
| 8 | Vertex Pharmaceuticals | 114.83 Bn | 107.58 Bn | 2.59 Bn |
| 9 | Abivax | 91.96 Bn | 91.96 Bn | - |
| 10 | Kymera Therapeutics | 8.84 Bn | 8.19 Bn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 189,052.00 |
| Mar 31, 2026 | 189,052.00 |
| Dec 31, 2025 | 284,026.00 |
| Dec 31, 2025 | 284,026.00 |
| Sep 30, 2025 | 278,130.00 |
| Sep 30, 2025 | 278,130.00 |
| Jun 30, 2025 | 224,882.00 |
| Jun 30, 2025 | 224,882.00 |
| Mar 31, 2025 | 146,869.00 |
| Mar 31, 2025 | 146,869.00 |
| Dec 31, 2024 | 174,463.00 |
| Dec 31, 2024 | 174,463.00 |
| Sep 30, 2024 | 168,731.00 |
| Sep 30, 2024 | 168,731.00 |
| Jun 30, 2024 | 163,903.00 |
| Jun 30, 2024 | 163,903.00 |
| Mar 31, 2024 | 83,209.00 |
| Mar 31, 2024 | 83,209.00 |
| Dec 31, 2023 | 39,511.00 |
| Dec 31, 2023 | 39,511.00 |